Medical Science Liaison Lead
About the job
- A bachelor's degree in life sciences, healthcare, or clinical sciences is required.
- At least 6 years of relevant clinical, laboratory, or healthcare experience, with progressive leadership, influence, or responsibility.
- Clinical or clinical laboratory experience is required. Relevant clinical experience may include patient-focused practice in infectious disease, critical care, emergency medicine, pharmacy, or other hospital or health-system settings. Relevant clinical laboratory experience includes clinical microbiology, diagnostic testing, laboratory medicine, or oversight or management of a hospital clinical laboratory.
- Demonstrated ability to lead and develop others and translate clinical or scientific expertise into a field medical environment.
- Consistently uphold and reflect the company's core ethical principles and values.
- Analyze data and make decisions or recommendations using data to guide decision-making and suggest improvements.
- Present technical data effectively.
- Work cross-functionally and organize work and resources efficiently.
- Demonstrate critical thinking, adaptability, time management, communication, problem-solving, and digital literacy.
- Use Microsoft Office tools, including Outlook, Teams, Word, and Excel, at an intermediate level.
- Demonstrate the ability to lead and inspire teams with an analytical and strategic mindset.
- Have deep scientific and clinical knowledge in diagnostics.
- Complete administrative tasks including expense reporting, internal training, vendor credentialing, data entry and review, and maintaining accurate records.
- Maintain administrative oversight of the area MSL team to ensure timely and compliant completion of expense reports, internal training, CRM documentation, and other administrative requirements.
- Ensure the team follows regulatory and company-specific guidelines when documenting insights, providing scientific information, and submitting reports.
- Demonstrate proficiency with relevant tools and software such as CRM and Microsoft Office applications, including Teams, PowerPoint, OneNote, Word, Excel, and Outlook.
- Perform work in compliance with company quality procedures and standards.
- Domestic travel of 70% is required.
- New hires must provide satisfactory proof of identity and legal authorization to work in the United States.
- Develop and maintain collaborative relationships with key opinion leaders, healthcare providers, and stakeholders in the assigned area.
- Mentor and develop area MSL team members in building a network of key opinion leaders and healthcare providers.
- Report regularly on key opinion leader development progress for the designated area.
- Cultivate partnerships with thought leaders to support the company's medical strategy and therapeutic objectives, and mentor the area team in developing key partnerships.
- Engage in scientific discussions to share relevant data and insights with internal and external stakeholders.
- Present scientific information on company products and therapeutic areas to internal and external audiences in alignment with strategic priorities.
- Coordinate MSL team activities across the assigned geographic area in alignment with strategic priorities.
- Mentor and coach team members in territory management, scientific presentations, and strategic delivery of medical education to regional stakeholders in alignment with medical plans.
- Collect and analyze insights from the team across the designated region to inform internal strategic direction.
- Provide medical affairs leadership with feedback on area trends, impactful findings, and evidence gaps identified through regional insight-gathering activities.
- Collaborate with other regional MSL Leads to interpret and relay field insights to internal stakeholders.
- Coach and mentor MSLs in gathering insights in alignment with individual medical plans and US and Global medical objectives.
- Stay current with research and scientific publications in relevant disease areas.
- Review and interpret scientific data to communicate product and disease-state information to internal teams and external stakeholders.
- Coach and develop the team in appraising and interpreting scientific literature, including developing Senior MSLs as peer mentors for junior MSL team members.
- Support strategic planning for team attendance at relevant regional medical and scientific conferences to network with key opinion leaders, gather insights, and share company advancements.
- Use conference participation to strengthen relationships and stay informed about emerging medical trends.
- Collaborate with US and Global Medical Affairs, Sales, Marketing, CSO, Regulatory Affairs, and other cross-functional teams to align on company goals and share insights affecting strategic direction.
- Participate in integrated medical teams and mentor team members' participation, fostering communication between integrated teams and the area MSL team.
- Ensure alignment and execution of priority tactics in integrated medical planning.
- Recruit and onboard new team members in the designated geographic area according to regional medical and business needs.
- Conduct performance assessments throughout the year and address concerns with the Associate Director and Human Resources Business Partner.
- Collaborate with other area MSL and Product Leads and the Medical Education and Training Manager to support the new-hire training pathway.
- Ensure ongoing team competency and compliance through field ride-alongs, coaching, and auditing CRM activity.
- Work with team members to identify professional development plans.
- Model the company's professional standards and ethical decision-making practices.
- Maintain an understanding of the needs and trends of the geographic area.
- Perform other duties as assigned.
- An advanced degree such as a PhD, PharmD, NP, PA, MS/MLS/DCLS, MD/DO, or a similar relevant advanced degree is strongly preferred.
- MSL or field medical affairs experience is preferred, particularly involving healthcare provider and key opinion leader engagement, scientific or medical education, insights gathering, and field-based medical strategy.
- Clinical microbiology board certification or a similar relevant clinical laboratory credential is preferred for candidates primarily from clinical laboratory medicine.
- Experience in infectious disease diagnostics, microbiology, molecular diagnostics, immunoassay, or related diagnostic areas is preferred.
- Knowledge of the regional health system landscape is desired.
- Knowledge of the infectious disease diagnostics market is preferred.
About the company
bioMérieux provides medical diagnostics worldwide by developing, manufacturing, and selling diagnostic tests, instruments, and software that detect infectious diseases and antimicrobial resistance. Its products work by analyzing patient samples through diagnostic assays and integrated systems that combine reagents, specialized instruments, and software to produce actionable test results for healthcare providers, laboratories, and public health agencies. The company stands out from competitors through its global leadership in in vitro diagnostics, a broad portfolio of instruments, reagents, and software, and a strong emphasis on public health and antimicrobial resistance challenges. Its goal is to improve patient care and public health by delivering timely, accurate diagnoses that help guide treatment and curb the spread of infectious diseases.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Marcy-l'Étoile, France
Founded
1963
Get referred to bioMérieux
See people who can refer or advise you
Simplify's Take
What believers are saying
- May 29, 2026, bioMérieux started a €250 million La Balme PCR factory.
- July 28, 2026 Q2 sales grew 5%, or 7.3% excluding respiratory panels.
- September 16, 2026 CE marking for BIOFIRE RP2.1plus and PNplus strengthens Europe.
What critics are saying
- Q1 2026 BIOFIRE respiratory sales fell 23%, exposing demand volatility.
- bioMérieux cut 2026 guidance after a weak start and a €50-€60 million FX headwind.
- A failed SpinChip commercialization would waste €138 million and weaken point-of-care ambitions.
What makes bioMérieux unique
- BIOFIRE multiplex PCR and SPOTFIRE point-of-care systems anchor a 28,500-unit installed base.
- bioMérieux couples clinical diagnostics, food safety, and pharma QC across 160 countries.
- xPRO partnerships and acquisitions accelerate menu expansion faster than rivals.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Adoption Assistance
Wellness Program
Employee Assistance Program
Commuter Benefits
Parental Leave
Employee Discounts
Company News
Transaction Valuation: SpinChip valued at NOK 1,624 million (EUR 138 million), making it one of the largest MedTech transactions in Norway. Menu Development: bioMérieux will accelerate the menu build-up of SpinChip’s Point of Care diagnostics platform. Strategic Growth: bioMérieux strengthens its position in the Point of Care market. Oslo, Norway, 13 January 2025 — SpinChip Diagnostics ASA (“SpinChip”), an innovative diagnostics company developing next-generation Point of Care platforms for in vitro diagnostics, announces its agreement to be acquired by bioMérieux, a global leader in in vitro diagnostics. Under the agreement, bioMérieux will acquire 100% ownership of SpinChip for a Total Enterprise Value of NOK 1,624 million. Morten Jurs, Chief Executive Officer of SpinChip, stated: “The dedication of the SpinChip team over the past decade has been exceptional. Their relentless efforts have led to the development of a groundbreaking diagnostics platform that has the potential to signif
Who owns Moderna right now in 2026? Moderna is publicly traded and widely held, not controlled by a family, state, or private equity sponsor. That makes who owns Moderna easier to see in filings, and it keeps control tied to the market rather than a single block holder. Moderna trades on the NASDAQ stock exchange under the ticker symbol MRNA and is a component of the S&P 500 index. The largest individual insider shareholders of Moderna are Stéphane Bancel (CEO) with approximately 7.3%, Noubar Afeyan (Co-founder and Chairman) with approximately 5%, Robert S. Langer (Co-founder) with approximately 4%, and Stephen Hoge (President) with approximately 1.3%. On the institutional side, the largest institutional shareholders of Moderna include Vanguard Group Inc., BlackRock, Inc., FMR LLC (Fidelity), Baillie Gifford & Co., State Street Corp., Capital World Investors, Geode Capital Management, and Morgan Stanley. No single person or entity controls Moderna outright. It is a widely distributed public company where the biggest voices are large index funds and asset managers - the same institutional giants that dominate most large American public companies. Ownership and key stakeholders table. The origin story: A conversation that changed medicine. Moderna was founded in 2010 by Noubar Afeyan, founder and CEO of Flagship Pioneering, in collaboration with Robert Langer, a professor of chemical engineering at MIT, and Derrick Rossi, a stem cell biologist, with the aim of developing messenger RNA (mRNA) therapeutics as a novel drug modality. The company originated from exploratory work within Flagship's VentureLabs, initially codenamed LS18, and was renamed Moderna Therapeutics to reflect its focus on modified RNA technologies. The spark was a meeting between Noubar Afeyan and Derrick Rossi, who had been doing breakthrough research on using chemically modified mRNA to reprogram cells. Noubar Afeyan met with Bob Langer and Derrick Rossi to review recent data on the use of chemically modified mRNA to reprogram adult human fibroblast cells into induced pluripotent stem cells. Noubar envisioned a different use of engineered mRNA as a new kind of medicine and launched within Flagship's VentureLabs group a month-long exploration which eventually led to Newco LS18, Inc. - which became Moderna. Stéphane Bancel, who had been Chief Executive Officer of the French diagnostics company bioMérieux SA, joined Moderna's board of directors in March 2011, and became its CEO in October 2011. Bancel was the operational genius who took a brilliant scientific idea and turned it into a scalable company. Under his leadership, Moderna secured partnerships, built laboratories, raised hundreds of millions of dollars, and survived years of skepticism from the broader scientific and investment community - many of whom believed mRNA medicine was too speculative to ever work. The COVID-19 moment that changed everything. For its first decade, Moderna was known only within the biotechnology world. Then came 2020 - and everything changed overnight. When SARS-CoV-2 emerged in early 2020, Moderna's scientists began designing a vaccine within days of the viral genome being published. The mRNA platform they had spent a decade building was perfectly suited for the task - because instead of growing virus in a lab to make a traditional vaccine, Moderna just needed to encode the spike protein instructions into mRNA and inject them. Moderna received an award from U.S. government agency BARDA for up to $483 million to accelerate development. It then announced a supply agreement with the U.S. government for an initial 100 million doses of its COVID-19 vaccine. The result was Spikevax - one of the first two mRNA COVID-19 vaccines in history - which achieved 94.5% efficacy in clinical trials and was authorized for emergency use by the FDA in December 2020. Almost overnight, Moderna went from a well-funded biotech startup to one of the most important companies in the world. The IPO and the Road to the S&P 500. Moderna became a public company through its 2018 IPO, which opened the cap table to public investors and shifted control from founders to shareholders. At the time of its IPO, Moderna had never had a single approved product. It went public purely on the strength of its mRNA platform and pipeline - an extraordinary level of investor conviction. The 2018 IPO raised approximately $600 million - the largest biotech IPO in history at that time. The underwriters priced shares at $23 each. By the peak of the COVID-19 vaccine rollout in 2021, MRNA shares had hit $497 - a gain of more than 2,000% in under three years. That surge created enormous paper wealth for the founders. Stéphane Bancel's net worth briefly exceeded $10 billion at the peak. Noubar Afeyan and Robert Langer also saw their stakes become worth billions. The Moderna story had become one of the greatest wealth-creation events in biotechnology history. Where is Moderna today in 2026? The post-COVID world has been a harder one for Moderna. Demand for COVID-19 vaccines has normalized dramatically, and the company has posted significant losses as it works to build out its broader pipeline. Moderna reported revenue of $1.94 billion in 2025, with a net loss of $2.8 billion and total assets of $12.3 billion. The company employs approximately 4,800 people. But Moderna's pipeline tells a more optimistic story. The company is advancing mRNA-based cancer vaccines - personalized treatments designed specifically for an individual patient's tumor - and has reported promising early results in trials with Merck. CEO Stéphane Bancel stated in early 2026: "I believe 2026 will also be the year when the world sees the promise of Moderna as a leading oncology company." In August 2026, the FDA approved Moderna's new mRNA-based flu vaccine - the first mRNA flu shot available to the public - marking another major milestone in the company's mission to use mRNA to fight a wide range of diseases beyond COVID-19. Frequently asked questions (faqs). Q1. Who owns Moderna in 2026? Moderna (NASDAQ: MRNA) is publicly owned with no single controlling shareholder - Vanguard and BlackRock are the largest institutional holders. Q2. Who founded Moderna? Moderna was founded in September 2010 by Noubar Afeyan, Robert Langer, Derrick Rossi, Kenneth Chien, and Timothy Springer, backed by Flagship Pioneering. Q3. Who is the CEO of Moderna in 2026? Stéphane Bancel is the CEO of Moderna, a role he has held since October 2011 after being recruited by co-founder Noubar Afeyan. Q4. What percentage of Moderna does Stéphane Bancel own? Stéphane Bancel owns approximately 7.3% of Moderna, making him the largest individual insider shareholder. Q5. When did Moderna go public? Moderna held its IPO in December 2018 on NASDAQ, pricing shares at $23 - the largest biotech IPO in history at that time. Q6. What is Moderna's revenue in 2025? Moderna reported $1.94 billion in revenue for 2025, with a net loss of $2.8 billion as it funds its broader pipeline beyond COVID-19 vaccines. Q7. Does the U.S. government own part of Moderna? No. The U.S. government funded Moderna's COVID-19 vaccine development through BARDA grants and supply agreements but holds no equity ownership in the company. Q8. What new products is Moderna launching in 2026? In August 2026, the FDA approved Moderna's first mRNA-based flu vaccine - and the company is advancing personalized mRNA cancer vaccines in partnership with Merck. Moderna is a publicly traded company on NASDAQ (ticker: MRNA) with no single controlling owner. It was founded in September 2010 by Noubar Afeyan, Robert Langer, Derrick Rossi, Kenneth Chien, and Timothy Springer - backed from day one by Flagship Pioneering, the venture capital firm that incubated the entire concept. The largest individual insider shareholders today are CEO Stéphane Bancel (~7.3%), Co-founder and Chairman Noubar Afeyan (~5%), and Co-founder Robert Langer (~4%). The biggest institutional holders are Vanguard, BlackRock, Fidelity, and Baillie Gifford. No single entity holds majority control - making Moderna a true public company, accountable to its broad shareholder base. From a codenamed startup experiment in 2010 to a COVID-19 vaccine that reached hundreds of millions of people, to an mRNA flu shot approved by the FDA in 2026 - Moderna's story is far from over.
bioMérieux highlights positive impacts of rapid, accurate diagnostics for Patients and accepts industry awards at ADLM 2026. Aug 07, 2026, 14:10 ET SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ - bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Conference & Clinical Lab Expo for an important conversation about the impact of access to diagnostics while also accepting multiple IMV ServiceTrak(TM) awards. PRESS CONFERENCE The company hosted a press panel, The Power of Diagnostics: How Delays Impact Patients and Providers, to discuss the real-world impacts of delayed or inaccurate diagnostic answers for patients, providers, communities, and the healthcare system. Dr. Charles K. Cooper, Executive Vice President and Chief Medical Officer at bioMérieux, moderated the panel with: * Dr. Omai Garner, Clinical Professor and Director of Clinical Microbiology, UCLA; * Dr. Michael Astion, PhD, Medical Director, Regional Laboratories and Point of Care, Medical Director, Reference Laboratories and PLUGS (Patient-Centered Laboratory Utilization Guidance Services), Department of Laboratories, Seattle Children's Hospital, Professor of Laboratory Medicine and Pathology, University of Washington; * Helaine Bader, MPH Vice President of Education, HealthyWomen; and * Dr. John Hurst, Senior Director, Field Medical Affairs at bioMérieux. Dr. Cooper noted that the panel discussed the "tremendous amount of pressure health care systems face and how access to rapid diagnostics at the point of care often alleviates some of this stress by getting health care clinicians and their patients answers while they wait." "Delay in getting a diagnosis may result in patients not receiving treatment at all because they may not come back for follow-up," said Ms. Bader. "Faster time to diagnosis during a single visit not only provides the patient with immediate answers but also builds trust between the patient and provider and reduces patient frustration, potential complications from the infection and the need for repeat visits." INDUSTRY RECOGNITION During the show, bioMérieux also accepted seven 2026 IMV ServiceTrak(TM) Clinical Laboratory Awards. These awards highlight bioMérieux's continued commitment to delivering industry-leading diagnostic solutions and exceptional customer support to clinical laboratories. 2026 ServiceTrak Awards: ID/AST Systems * Best Customer Satisfaction * Best System Performance * Best Service 2026 ServiceTrak Awards: Blood Culture Systems * Best Customer Satisfaction * Best System Performance * Best Service 2026 Best System Performance * Immunoassay Analyzers "We are thrilled that IMV and the Science and Medicine Group has recognized bioMérieux for the ninth consecutive year for the continued dedication and excellence of our product management, operations, and customer support teams," said Randy Pritchard, General Manager and Sr. Vice President of Clinical Operations, bioMérieux. "This recognition, across our immunoassay, ID/AST Systems, and Blood Culture Systems offerings, highlights our commitment to pioneering diagnostics in the fight against sepsis and antimicrobial resistance." ABOUT BIOMÉRIEUX Pioneering Diagnostics A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. www.biomerieux.com. bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM - ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP SOURCE bioMérieux
bioMérieux to Showcase Company's Latest in Diagnostic Innovations at ADLM 2026. PR Newswire Today at 8:43am PDT ANAHEIM, Calif., July 14, 2026 /PRNewswire/ - bioMérieux, a global leader in in vitro diagnostics, today announced it will showcase its latest diagnostic solutions and innovations at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Conference & Clinical Lab Expo, taking place in Anaheim, California, July 26 through 30. Attendees are invited to visit bioMérieux at booth #2501 in Hall B to explore the company's comprehensive portfolio and connect with experts across clinical microbiology, molecular diagnostics, and laboratory informatics. Featured Technologies at Booth #2501 This year's company presence is anchored by the theme: "A legacy of diagnostic leadership. Your partner for what's ahead." The theme reflects bioMérieux's continued commitment to advancing diagnostic excellence over the past 63 years, while supporting laboratories and healthcare practitioners in navigating the future of medicine. At the expo, bioMérieux will highlight a range of innovative platforms designed to showcase the company's end-to-end laboratory ecosystem including: BIOFIRE(R) FILMARRAY(R) TORCH System, a multiplex PCR technology that tests for a comprehensive group of targets in about an hour, BIOFIRE(R) SPOTFIRE(R) System, a multiplex PCR platform that brings reliable diagnostics to point-of-care clinical settings, VITEK(R) MS PRIME, a mass spectrometry system for routine microbial identification, and the VIDAS(R) 3, an automated benchtop immunoassay system. Visitors will be able to explore how bioMérieux's solutions connect microbiology, molecular diagnostics, laboratory automation, informatics, and stewardship initiatives to help laboratories improve efficiency, accelerate decision-making, and optimize patient care. In addition, visitors can explore bioMérieux's latest data and IT solutions, and Lab Consultancy offerings, designed to help laboratories optimize operations, improve outcomes, and drive digital transformation. Educational Symposiums As part of its commitment to advancing clinical knowledge and best practices, and demonstrating the value of diagnostics, bioMérieux will host two symposiums included in the conference's agenda: * From Central Lab to POC: Rethinking Vaginitis Diagnostics * Tuesday, July 28 from 12:00 p.m. until 12:20 p.m. in Exhibit Hall Theater 2 * Attendees will examine current diagnostic limitations, the consequences of delayed results, and how point-of-care testing aligns with real-time decision making. * The Syndromic Standard: Explore the Clinical Impact of MPCR GI Panels for Gastroenteritis * Tuesday, July 28 from 2:45 p.m. until 3:35 p.m. in Exhibit Hall Theater 1 * Attendees will learn about the latest developments in reducing diagnostic uncertainty, improving time-to-treatment, and advancing patient outcomes. Press Conference and Panel Discussion The company will also host a press conference panel, The Power of Diagnostics: How Delays Impact Patients and Providers, on Wednesday, July 29 from 9:00 a.m. until 9:45 a.m. in room 213D. Panel experts from bioMérieux, rural medicine, and patient advocacy will discuss the real-world impacts of delayed or inaccurate diagnostic answers for patients, providers, communities, and the healthcare system, especially as they affect women, minority communities, and other underserved populations. The panel will feature real-world examples from patient and provider experiences and potential solutions for today and the future. Conference attendees and members of the media are invited to attend. For media looking to register for event credentials: visit https://myadlm.org/media/press-registration. For more information on the bioMérieux press conference contact: [email protected]. ABOUT BIOMÉRIEUX Pioneering Diagnostics A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM - ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP SOURCE bioMerieux This is a paid placement. For further inquiries, please contact PR Newswire directly.
BioMérieux's new commercial DNA test rapidly screens dietary supplement label claims. Key takeaways. * BioMérieux has launched a new commercial DNA test that verifies probiotic dietary supplement label claims in under 90 minutes. * Developed with the natural products brand NOW, the on-site test identifies 18 common probiotic species to reduce operational costs and delays. * The system provides manufacturers and third-party labs with a rapid, standardized alternative or complement to traditional sequencing. Laboratory diagnostics specialist BioMérieux has launched Gene-Up Probiotic Species ID, a new solution for verifying dietary supplement label claims in less than 90 minutes, addressing the cost, complexity, and delays of traditional workflows. This new commercial DNA test allows internal quality teams and external labs to easily identify specific probiotic species in their own facilities. BioMérieux developed the system in collaboration with Now, a natural supplements brand with more than 50 years of experience in product testing. Now was previously reliant on third-party reference laboratories for multi-strain species identification on mixed formulations. It partnered with bioMérieux to develop a faster, more capable verification solution that prioritizes scientific rigor and operational efficiency. "Waiting weeks for compendial-based species identification created bottlenecks across our operations, from delayed production release to increased holding costs and unnecessary product risk," says Maria Mendres, microbiology manager at Now. "Our partnership with BioMérieux to develop Gene-Up Probiotic Species ID gives us, as well as the industry at large, the ability to generate accurate, on-site species-level results in 90 minutes or less." Mendres adds that this speed and accessibility have helped the brand hit production targets and minimize waste, while strengthening its ability to consistently deliver validated label claims. Traditional challenges of species-level identification. According to BioMérieux, demonstrating probiotic efficacy requires reliable species-level identification. However, it notes that many existing quality control approaches are costly, complex, or slow. This puts an operational strain on quality teams and limits routine testing. Gene-Up Probiotic Species ID accurately identifies 18 of the most commonly used probiotic species across capsules and powders in 90 minutes or less.The company stresses that these pressures are driving demand for faster, more practical testing solutions that support quality, transparency, and consistency without compromising scientific robustness. Gene-Up Probiotic Species ID accurately identifies 18 of the most commonly used probiotic species across capsules and powders, including Lactobacillus acidophilus, L. rhamnosus, and Bifidobacterium lactis, in 90 minutes or less. "Probiotic manufacturers are navigating a rapidly evolving landscape where ensuring reliable species verification is becoming essential, not only for quality control, but also for minimizing operational risk, supporting accurate label claims, and maintaining market access in a highly competitive category," says Alejo Migones, SVP of Global Food Safety & Quality at BioMérieux. Third-party screening applications. In addition to manufacturers, Gene-Up Probiotic Species ID has been adopted by third-party reference laboratories seeking to broaden their probiotic testing capabilities. Because the assays offer a rapid and standardized approach to bacterial species identification, they serve as a complementary option to sequencing for routine testing and high-throughput screening. The solution is designed for laboratory workflows and supports timely label verification. BioMérieux says this helps laboratories manage increasing sample volumes, while reserving sequencing resources for more complex analytical needs. BioMérieux's xPRO Program. This is the latest diagnostic innovation from BioMérieux's xPro Program, which connects industry leaders with BioMérieux partners to accelerate the development and commercialization of next-generation molecular diagnostics that solve pressing quality and safety challenges. BioMérieux operates in 46 countries and serves more than 160 countries with the support of a large network of distributors. The company offers diagnostic solutions that determine the source of disease and contamination in supply chains. Its products are mainly used for diagnosing infectious diseases. In addition to species identification with Gene-Up Probiotic Species ID, the company provides tools for detection, enumeration, and environmental monitoring. "In the US, where the probiotics market continues to grow, and consumer scrutiny continues to rise, Gene-Up Probiotic Species ID gives manufacturers the confidence to stand behind their products and deliver precise species identification that supports label integrity and protects brand reputation," says Miguel Villa, SVP of Industrial Applications, North America at BioMérieux. The launch follows a recent analysis of over 350 products from US drugstores, which found that probiotic supplements contain limited microbial diversity and lack a clear link to the intended health benefit. The authors of the study have created HaPaPro, a tool that identifies beneficial microbes using over 1,000 computer models.